Innate Lymphoid Cell (ILC) Therapy for GvHD

Hematopoietic stem cell transplantation (HSCT) is curative for a variety of disorders. However, a substantial number of patients undergoing HSCT develop graft versus host disease (GvHD) after treatment. GvHD carries around a 50% mortality rate. Drs. Michael Verneris and Dejene Tufa have pioneered methods to generate and isolate innate lymphoid cells (ILCs) for either the prophylaxis of graft versus host disease (GvHD) in anticipation of hematopoietic stem cell transplantation (HSCT) or as direct treatment of GvHD following HSCT. In-vivo studies suggests improved survival of GvHD mouse models with ILC administration. The novel therapy could also have utility in the treatment of other conditions where intestinal inflammation plays an important part such as Crohn's disease.
For Information, Contact:
Doreen Molk
University of Colorado
Michael Verneris
Dejene Tufa
Disease Areas:
For inquiries, email:     © 2023. All Rights Reserved. Powered by Inteum